GLP-1 agents such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are game-changers. In addition to weight loss, they may reduce neurodegenerative diseases, such as Parkinson’s and Alzheimers dementia, due to a reduction in metabolic syndrome, reduction in vascular events and neuroprotective effects.

“GLP-1 plays important role in augmenting insulin signalling inside the brain. GLP-1 receptors, present inside the brain, are also involved in cognition, synaptic transmission in hippocampal neurons, and cell apoptosis. Overexpression of this receptor is responsible for cognition enhancement and neuroprotection, while deficiency increases the chances of seizure and neurodegeneration (81, 82). Therefore, GLP-1 receptors are considered as validated target for exploring candidates with better neuroprotection and cognition enhancing abilities (83).”

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159769/